Bahl & Gaynor’s Boston Scientific BSX Stock Holding History

Bahl & Gaynor’s Portfolio BSX Stock Details BSX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-3,517	Closed	-$221K	–	343
2026 Q1	$221K	Hold	3,517	–	–	﹤0.01%	317
2025 Q4	$335K	Sell	3,517 -547	-13%	-$53.6K	﹤0.01%	302
2025 Q3	$397K	Hold	4,064	–	–	﹤0.01%	295
2025 Q2	$437K	Hold	4,064	–	–	﹤0.01%	292
2025 Q1	$410K	Buy	4,064 +1,655	+69%	+$167K	﹤0.01%	296
2024 Q4	$215K	Hold	2,409	–	–	﹤0.01%	325
2024 Q3	$202K	Buy	+2,409	New	+$190K	﹤0.01%	335

Other funds holding BSX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Bahl & Gaynor's BSX Position: Q2 2026 in Review

Bahl & Gaynor sold out of Boston Scientific (BSX) in Q2 2026, closing a stake of 3,517 shares — an estimated $221K sold.

Bahl & Gaynor first reported a position in BSX in Q3 2024 and held it in 7 quarters. The position peaked at $437K in Q2 2025. 1,474 funds tracked by Wall St. Rank hold BSX as of Q2 2026.

Bahl & Gaynor reported no remaining Boston Scientific position as of Q2 2026 after selling out during the quarter.
Bahl & Gaynor sold 3,517 Boston Scientific shares in Q2 2026, an estimated $221K.
Bahl & Gaynor first reported a position in Boston Scientific in Q3 2024 and held it in 7 quarters.
Bahl & Gaynor's Boston Scientific position peaked at $437K in Q2 2025.
1,474 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.

Based on Bahl & Gaynor's 13F filing for Q2 2026, filed 13 Aug 2026.